Pfiz­er to com­plete Seagen ac­qui­si­tion Thurs­day, An­gela Hwang to de­part amid ex­ec­u­tive shuf­fle

Pfiz­er said Tues­day morn­ing it ex­pects to seal its $43 bil­lion Seagen ac­qui­si­tion on Thurs­day af­ter hav­ing cleared all reg­u­la­to­ry ap­provals, and the Big Phar­ma al­so said it would make ad­just­ments to its lead­er­ship team.

Chief com­mer­cial of­fi­cer and glob­al bio­phar­ma pres­i­dent An­gela Hwang will de­part af­ter near­ly 27 years at the New York phar­ma gi­ant as Pfiz­er cre­ates two non-on­col­o­gy com­mer­cial units. The move comes as Pfiz­er re­duces its head­count by the thou­sands at mul­ti­ple sites around the world in the wake of dwin­dling Covid-19 sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER